D. Alberti

1.0k citations

26 papers · 777 indexed · h-index 13

Impact in

Nephrology top 2%
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Renal Diseases and Glomerulopathies
Hematology top 5%
- Iron Metabolism and Disorders
- Acute Myeloid Leukemia Research

Papers in ⓘ

Genetics 11
- Hemoglobinopathies and Related Disorders 10
Nephrology 7
- Dialysis and Renal Disease Management 5
- Chronic Kidney Disease and Diabetes 4

Co-authors: Francesco Locatelli (7 shared papers)G. Graziani (4 shared papers)A Giangrande (4 shared papers)G. Buccianti (4 shared papers)B Redaelli (4 shared papers)Daniele Marcelli (3 shared papers)Mario Comelli (1 shared paper)Gianni Tognoni (1 shared paper)
Journals: Blood (7 papers)Kidney International (2 papers)Nephrology Dialysis Transplantation (2 papers)European Journal of Clinical Pharmacology (2 papers)Journal of Cardiovascular Pharmacology (1 paper)
Partner nations: Italy Switzerland United States

In The Last Decade

D. Alberti

25 papers receiving 736 citations

Peers

Countries citing papers authored by D. Alberti

Since Specialization

Citations

This map shows the geographic impact of D. Alberti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Alberti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Alberti more than expected).

Fields of papers citing papers by D. Alberti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Alberti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Alberti. The network helps show where D. Alberti may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Alberti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Alberti Line = papers co-authored together D. Alberti links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency The Lancet ·Francesco Locatelli, D. Alberti, G. Graziani, G. Buccianti, B Redaelli, A Giangrande	1991	162
2	Proteinuria and blood pressure as causal components of progression to end-stage renal failure Nephrology Dialysis Transplantation ·Francesco Locatelli, Daniele Marcelli, Mario Comelli, D. Alberti, G. Graziani, G. Buccianti, B Redaelli, A Giangrande	1996	134
3	Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging Haematologica ·Emanuela Messa, Sonia Carturan, Chiara Maffè, Marisa Pautasso, Enrico Bracco, Antonella Roetto, F. Messa, Francesca Arruga, Ilaria Defilippi, Valentina Rosso, Chiara Zanone, Antonia Rotolo, E. Greco, Rosa Maria Pellegrino, D. Alberti, Giuseppe Saglio, Daniela Cilloni	2010	116
4	Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes Kidney International ·Merlin C. Thomas, Con Tsalamandris, Richard J. MacIsaac, Tanya L. Medley, Bronwyn A. Kingwell, Mark E. Cooper, George Jerums, D. Alberti	2004	59
5	Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial Journal of Cardiovascular Pharmacology ·Giuseppe Maschio, D. Alberti, Francesco Locatelli, Johannes F.E. Mann, M Motolese, Claudio Ponticelli, Eberhard Ritz, G. Janin, P Zucchelli	1999	58
6	Pharmacosurveillance and quality of care of thalassaemic patients European Journal of Clinical Pharmacology ·Rosa Arboretti, Gianni Tognoni, D. Alberti	2001	47
7	Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. PubMed ·Francesco Locatelli, Carbarns Ir, G Maschio, Mann Jf, Claudio Ponticelli, Eberhard Ritz, D. Alberti, M Motolese, G. Janin, P Zucchelli	1997	36
8	Long-term progression of chronic renal insufficiency in the AIPRI extension study Kidney International ·Francesco Locatelli, I. R I Carbarns, G Maschio, Johannes F.E. Mann, Claudio Ponticelli, Eberhard Ritz, D. Alberti, M Motolese, G. Janin, P Zucchelli	1997	21
9	Factors affecting chronic renal failure progression: results from a multicentre trial. The Northern Italian Cooperative Study Group. PubMed ·Francesco Locatelli, D. Alberti, G. Graziani, G. Buccianti, B Redaelli, A Giangrande, Daniele Marcelli, Francucci Bm	1992	21
10	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. PubMed ·Gianantonio Rosti, Elena Trabacchi, Sebastián Bassi, Francesca Bonifazi, De Vivo A, Giovanni Martinelli, D. Alberti, G. Fincato, Giuseppe Saglio, Michele Baccarani, (unknown)	2003	20
11	Hypertension as a factor in chronic renal insufficiency progression in polycystic kidney disease Nephrology Dialysis Transplantation ·Daniele Marcelli, Francesco Locatelli, D. Alberti, G. Graziani, G. Buccianti, B Redaelli, A Giangrande, (unknown)	1995	19
12	A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade®, ICL670) Is Well Tolerated and Reduces Iron Burden. Blood ·Elliott Vichinsky, R Fischer, Ellen B. Fung, Onyinye Onyekwere, John B. Porter, Paul Swerdlow, Thomas D. Coates, Peter A. Lane, B. Files, Brigitta U. Mueller, Françoise Bernaudin, Gian Luca Forni, C. Ressayre-Djaffer, Insa Gathmann, Jaymes Holland, D. Alberti, Peter Marks	2005	19
13	Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study Journal of Endocrinological Investigation ·Silvia Grottoli, Roberta Celleno, Valentina Gasco, Rosario Pivonello, Davide Caramella, Alessandra Barreca, Federico Ragazzoni, Francesca Pigliaru, D. Alberti, Roberto Ferrara, G Angeletti	2005	17
14	Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia. Blood ·Pierre Brissot, Bruno Turlin, Gian Luca Forni, Giuliana Alimena, Giovanni Quarta, Dominik Selleslag, Alexis A. Thompson, Franco Locatelli, Adriana Berretta, M. de Montalembert, C. Ressayre-Djaffer, B. Rabault, J. Ford, D. Alberti	2005	9
15	Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade®, ICL670) and Deferoxamine (DFO). Blood ·Elliott Vichinsky, Roland A. Fischer, Zahra Pakbaz, Onyinye Onyekwere, John B. Porter, Paul Swerdlow, Thomas D. Coates, Peter A. Lane, B. Files, Brigitta U. Mueller, Léna Coïc, Gian Luca Forni, Linda Abetz, J.F. Baladi, C. Ressayre-Djaffer, Insa Gathmann, D. Alberti, Peter Marks	2005	8
16	Deferasirox (Exjade®, ICL670) Demonstrates Dose-Related Effects on Body Iron Levels Related to Transfusional Iron Intake in Transfusion-Dependent Anemia. Blood ·Peter L. Greenberg, G. Dine, Arnold Ganser, G. Verhoef, L Debusscher, Giovanni Quarta, Pierre Zachée, Giuliana Alimena, Michael Jeng, Gil Tchernia, Insa Gathmann, D. Alberti, B. Rabault	2005	8
17	Impact on Iron Removal of Dose Reduction for Non-Progressive Serum Creatinine Increases during Treatment with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670). Blood ·Norbert Gattermann, N. Zoumbos, Emanuele Angelucci, Guillermo Drelichman, J. Siegel, Ekkehard Glimm, D. Alberti	2006	7
18	Chlorthalidone Alone or in Fixed Combination with Slow-Release Metoprolol in the Management of Arterial Hypertension: A Long-Term Study of 545 Patients Journal of International Medical Research ·E. Bichisao, Laura Merlini, Orsola Gambini, D. Alberti, G Pollavini	1989	3
19	ACCURACY OF THE ANAMNESTIC ASCERTAINMENT OF PARENTAL HISTORY OF HYPERTENSION1 American Journal of Epidemiology ·M Radice, D. Alberti, C Alli, Fausto Avanzini, Adriano Decarli, Marco Di Tullio, Gavino Mariotti, Emanuela Taioli, Emanuela Terzian, A Zussino	1986	3
20	Long-Term Treatment with the Once-Daily Oral Iron Chelator Deferasirox (Exjadereg], ICL670) Is Effective and Generally Well Tolerated in Pediatric Patients. Blood ·Antonio Piga, Mohamed Béjaoui, (unknown), Silverio Perrotta, Elliott Vichinsky, Caroline Arrowsmith-Bensasson, Ekkehard Glimm, D. Alberti	2006	3

About D. Alberti

D. Alberti is a scholar working on Genetics, Nephrology, Hematology, Geriatrics and Gerontology and Pediatrics, Perinatology and Child Health, having authored 26 papers that have together received 777 indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (10 papers), Iron Metabolism and Disorders (7 papers), Dialysis and Renal Disease Management (5 papers), Chronic Kidney Disease and Diabetes (4 papers), Pharmacological Effects and Toxicity Studies (3 papers), Acute Myeloid Leukemia Research (3 papers), Blood Pressure and Hypertension Studies (3 papers) and Biomedical Research and Pathophysiology (2 papers). The work is most often cited by research in Nephrology (330 citations), Hematology (234 citations), Genetics (207 citations), Cardiology and Cardiovascular Medicine (192 citations) and Clinical Biochemistry (50 citations). D. Alberti has collaborated with scholars based in Italy, Switzerland and United States. Frequent co-authors include Francesco Locatelli, G. Graziani, A Giangrande, G. Buccianti, B Redaelli, Daniele Marcelli, Mario Comelli, Gianni Tognoni, Rosa Arboretti and M Motolese. Their work appears in journals such as Blood, Kidney International, Nephrology Dialysis Transplantation, European Journal of Clinical Pharmacology and Journal of Cardiovascular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact